30 May 2024 in European Journal of Translational Myology
Botulinum Neurotoxin Type A (BoNT-A) injections using Ultrasound (US) guidance have led to research evaluating changes in muscle architecture. Controversy remains as to what constitutes increased Echo-Intensity (EI) in spastic muscles and whether this may affect outcomes. We aim to provide a narrative review of US muscle architecture changes following Central Nervous System (CNS) lesions and explore their relationship to spasticity. Medline, CINAHL, and Embase databases were searched with keywords: ultrasonography, hypertonia, spasticity, fibrosis, and Heckmatt. Three physicians reviewed the results of the search to select relevant papers. Reviews identified in the search were used as a resource to identify additional studies. A total of 68 papers were included. Four themes were identified, including histopathological changes in spastic muscle, effects of BoNT-A on the muscle structure, available US modalities to assess the muscle, and utility of US assessment in clinical spasticity. Histopathological studies revealed atrophic and fibro-fatty changes after CNS lesions. Several papers described BoNT-A injections contributing to those modifications. These changes translated to increased EI. The exact significance of increased muscle EI remains unclear. The Modified Heckmatt Scale (MHS) is a validated tool for grading muscle EI in spasticity. The use of the US may be an important tool to assess muscle architecture changes in spasticity and improve spasticity management. Treatment algorithms may be developed based on the degree of EI. Further research is needed to determine the incidence and impact of these EI changes in spastic muscles.
18 February 2026 in Muscle & Nerve
Introduction/Aims: When spasticity occurs after a stroke, peripheral changes in spastic muscle architecture may develop. The primary objective was to determine if an association exists between spastic muscle echointensity (EI) measured by the Modified Heckmatt Scale (MHS) and changes in insertional activity detected by electromyography (EMG). The secondary aim was to investigate whether these changes are due to the effects of botulinum neurotoxin (BoNT). Methods: A total of 55 patients with poststroke spasticity were enrolled from three outpatient spasticity clinics. Muscle EI and needle EMG insertional activity were assessed for 8 muscles in each subject. Chi‐square tests or Fisher's exact tests for categorical variables were used to evaluate the association between muscle EI and EMG insertional activity, as well as the association between BoNT exposure and muscle changes. Results: For MHS Grade 1–2 muscles, 91.7% had normal insertional activity compared to 46.4% of MHS Grade 3–4 muscles ( p < 0.001). In muscles with abnormal insertional activity, reduced or absent insertional activity was seen in 67.3% of MHS 3–4 muscles compared to only 16.7% for MHS 1–2 muscles, while increased insertional activity was seen in 32.7% of MHS 3–4 muscles and 83.3% of MHS graded 1–2 muscles. Exposure to BoNT did not impact the observed association between MHS and abnormal EMG insertional activity. Discussion: Increased EI is associated with abnormal EMG insertional activity. Exposure to BoNT does not explain the observed EI and EMG changes. Further research is needed to elucidate the significance and causes of muscle architectural and electromyographical transformation in poststroke spasticity.